Correspondence 0001104659-25-004901 from Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc.
Date: Jan. 21, 2025 · CIK: 0000894158 · Accession: 0001104659-25-004901
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283722
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Tamika Sheppard Registration Statement on Form S-1 Filed December 10, 2024, as amended File No: 333-283722
Re: Theriva Biologics, Inc.
Dear Ms. Sheppard:
Theriva Biologics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-283722), as amended, be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Thursday, January 23, 2025, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.
Very truly yours,
THERIVA BIOLOGICS, INC.
Show Raw Text
CORRESP 1 filename1.htm January 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tamika Sheppard Re: Theriva Biologics, Inc. Registration Statement on Form S-1 Filed December 10, 2024, as amended File No: 333-283722 Dear Ms. Sheppard: Theriva Biologics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-283722), as amended, be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Thursday, January 23, 2025, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted. Very truly yours, THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer cc: Leslie Marlow, Blank Rome LLP